首页 中华肿瘤杂志 2021年43卷07期 中国淋巴瘤治疗指南(2021年版)
中华肿瘤杂志
期刊首页
过刊列表
高级检索
稿件发表
• 指南与规范 •
ENGLISH ABSTRACT
中国淋巴瘤治疗指南(2021年版)
中国抗癌协会淋巴瘤专业委员会 
中国医师协会肿瘤医师分会
中国医疗保健国际交流促进会肿瘤内科分会
作者及单位信息
·
DOI： 10.3760/cma.j.cn112152-20210516-00382
Clinical practice guideline for lympoma in China (2021 Edition)
China Anti-cancer Association Lymphoma Committee
Chinese Association for Clinical Oncologists
Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
Shi Yuankai
Authors Info & Affiliations
China Anti-cancer Association Lymphoma Committee
Chinese Association for Clinical Oncologists
Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
Shi Yuankai
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
·
DOI： 10.3760/cma.j.cn112152-20210516-00382
24064
4468
0
4
217
61
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6 829例，死亡2 807例；新发非霍奇金淋巴瘤92 834例，死亡54 351例。淋巴瘤病理类型复杂，异质性强，治疗原则各有不同。近年来，随着人们对淋巴瘤本质认识的不断深入，淋巴瘤在诊断和治疗方面出现了很多新的研究结果，患者生存得到了改善。为了及时反映国内外淋巴瘤治疗领域的进展，进一步提高中国淋巴瘤的规范化诊断和治疗水平，中国抗癌协会淋巴瘤专业委员会、中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了中国淋巴瘤治疗指南(2021年版)。
淋巴瘤;诊断;治疗;指南
ABSTRACT
Lymphoma is one of the most common malignancies in China. In China, there were 6 829 new Hodgkin lymphoma cases and 2 807 deaths in 2020, with 92 834 new non-Hodgkin lymphoma cases and 54 351 deaths. Due to the complicated pathological subtypes and heterogeity, the treatment strategies for lymphoma vary largely. In recent years, with the deep understanding for the nature of lymphoma, much research progress has been achieved in the diagnosis and treatment, leading to a remarkable improvement in survival outcome of patients. In order to update the progress in the treatment of lymphoma worldwide timely, and further improve the level of standardized diagnosis and treatment of lymphoma in China, the China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical practice guideline for lympoma in China (2021 Edition)" .
Lymphoma;Diagnosis;Therapy;Guideline
Shi Yuankai, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China, Email:
nc.defcaab.smaciciaknauys
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
中国抗癌协会淋巴瘤专业委员会,中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志,2021,43(07)：707-735.
DOI:10.3760/cma.j.cn112152-20210516-00382PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
淋巴瘤，又称恶性淋巴瘤，是一组起源于淋巴造血系统的恶性肿瘤的总称，是中国常见恶性肿瘤之一。GLOBOCAN 2020数据显示，2020年全球新发霍奇金淋巴瘤(Hodgkin lymphoma, HL)83 087例，其中男性48 981例，女性34 106例；死亡23 376例，其中男性14 288例，女性9 088例
[
1
,
2
]。2020年全球新发非霍奇金淋巴瘤(non-Hodgkin lymphoma, NHL)544 352例，居全部恶性肿瘤新发病例的第13位；其中男性304 151例，居第10位；女性240 201例，居第12位
[
1
,
2
]。2020年全球NHL死亡259 793例，居全部恶性肿瘤死亡排名的第12位；其中男性147 217例，居第10位；女性112 576例，居第13位
[
1
,
2
]。2020年中国新发HL 6 829例，其中男性4 506例，女性2 323例；死亡2 807例，其中男性1 865例，女性942例；2020年中国新发NHL 92 834例，其中男性50 125例，女性42 709例；2020年中国NHL死亡54 351例，其中男性29 721例，女性24 630例；男性NHL发病率和死亡率均居全部恶性肿瘤第10位；女性NHL发病率和死亡率均未进入全部恶性肿瘤的前10位
[
1
,
2
]。
为规范中国淋巴瘤诊疗行为、提高诊疗水平、改善患者预后、保障医疗质量和医疗安全，国家卫生和计划生育委员会医政医管局委托中国抗癌协会肿瘤临床化疗专业委员会组织专家编写了《中国恶性淋巴瘤诊疗规范(2015年版)》
[
3
]，国家卫生健康委员会医政医管局委托国家癌症中心组织专家编写了《淋巴瘤诊疗规范(2018年版)》
[
4
]。近年来，随着人类对淋巴瘤本质认识的不断深入，淋巴瘤在诊断和治疗等方面出现了很多新的研究结果，患者生存得到了改善。淋巴瘤是一类以药物治疗为主的疾病，在过去15年中，中国抗淋巴瘤新药临床试验取得了长足发展，中国淋巴瘤患者有了更多的治疗选择
[
5
,
6
]。为了及时反映国内外淋巴瘤治疗领域的进展，进一步提高中国淋巴瘤的规范化诊断和治疗水平，中国抗癌协会淋巴瘤专业委员会、中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了《中国淋巴瘤治疗指南(2021年版)》。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Sung H , Ferlay J , Siegel RL ,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3)：209-249. DOI：
10.3322/caac.21660
.
[2]
Cao W , Chen HD , Yu YW ,et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021,134(7)：783-791. DOI：
10.1097/CM9.0000000000001474
.
[3]
石远凯，孙燕，刘彤华. 中国恶性淋巴瘤诊疗规范(2015年版)[J]. 中华肿瘤杂志， 2015,37(2)：148-158. DOI：
10.3760/cma.j.issn.0253-3766.2015.02.014
.
Shi YK , Sun Y , Liu TH . Guidelines for diagnosis and treatment of malignant lymphoma in China(Version 2015)[J]. Chin J Oncol, 2015,37(2)：148-158. DOI：
10.3760/cma.j.issn.0253-3766.2015.02.014
.
[4]
中华人民共和国国家卫生健康委员会. 淋巴瘤诊疗规范(2018年版)[EB/OL]. [ 2021-2-26]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=b21802b199814ab7b1219b87de0cae51.
National Health Commission of the People′s Republic of China. Guidelines for diagnosis and treatment of lymphoma(2018 Version)[EB/OL]. [ 2021-2-26]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=b21802b199814ab7b1219b87de0cae51.
[5]
Shi Y . Current status and progress of lymphoma management in China[J]. Int J Hematol, 2018,107(4)：405-412. DOI：
10.1007/s12185-018-2404-8
.
[6]
Chen H , Zhou Y , Han X ,et al. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): a systematic review[J]. The Lancet Regional Health-Western Pacific, 2021,8：1-9. DOI：
10.1016/j.lanwpc.2021.100097
.
[7]
Lister TA , Crowther D , Sutcliffe SB ,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin′s disease: Cotswolds meeting[J]. J Clin Oncol, 1989,7(11)：1630-1636. DOI：
10.1200/JCO.1989.7.11.1630
.
[8]
Cheson BD , Fisher RI , Barrington SF ,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014,32(27)：3059-3068. DOI：
10.1200/JCO.2013.54.8800
.
[9]
Rohatiner A , d′Amore F , Coiffier B ,et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma[J]. Ann Oncol, 1994,5(5)：397-400. DOI：
10.1093/oxfordjournals.annonc.a058869
.
[10]
Binet JL , Auquier A , Dighiero G ,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis[J]. Cancer, 1981,48(1)：198-206. DOI：
10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v
.
[11]
Rai KR , Sawitsky A , Cronkite EP ,et al. Clinical staging of chronic lymphocytic leukemia[J]. Blood, 1975,46(2)：219-234.
[12]
Olsen E , Vonderheid E , Pimpinelli N ,et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)[J]. Blood, 2007,110(6)：1713-1722. DOI：
10.1182/blood-2007-03-055749
.
[13]
Kim YH , Willemze R , Pimpinelli N ,et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)[J]. Blood, 2007,110(2)：479-484. DOI：
10.1182/blood-2006-10-054601
.
[14]
Younes A , Hilden P , Coiffier B ,et al. International working group consensus response evaluation criteria in lymphoma(RECIL 2017)[J]. Ann Oncol, 2017,28(7)：1436-1447. DOI：
10.1093/annonc/mdx097
.
[15]
Swerdlow SH , Campo E , Harris NL . WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Lyon:LARC Press, 2017.
[16]
Brice P , de Kerviler E , Friedberg JW . Classical Hodgkin lymphoma[J]. Lancet, 2021,22：
10.1016/S0140-6736(20)32207-8
. DOI：.
[17]
陶云霞，康愫意，周立强，等. 415例霍奇金淋巴瘤患者的疗效和预后因素分析[J]. 中华肿瘤杂志， 2015, (6)：466-471. DOI：
10.3760/cma.j.issn.0253-3766.2015.06.015
.
Tao YX , Kang SY , Zhou LQ ,et al. Clinical efficacy and prognostic factors in 415 patients with Hodgkin lymphoma[J]. Chin J Oncol, 2015, (6)：466-471. DOI：
10.3760/cma.j.issn.0253-3766.2015.06.015
.
[18]
Advani RH , Horning SJ , Hoppe RT ,et al. Mature results of a phase Ⅱ study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma[J]. J Clin Oncol, 2014,32(9)：912-918. DOI：
10.1200/JCO.2013.53.2069
.
[19]
Eichenauer DA , Fuchs M , Pluetschow A ,et al. Phase 2 study of rituximab in newly diagnosed stage ⅠA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group[J]. Blood, 2011,118(16)：4363-4365. DOI：
10.1182/blood-2011-06-361055
.
[20]
Cencini E , Fabbri A , Bocchia M . Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma[J]. Br J Haematol, 2017,176(5)：831-833. DOI：
10.1111/bjh.14001
.
[21]
Fanale MA , Cheah CY , Rich A ,et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma[J]. Blood, 2017,130(4)：472-477. DOI：
10.1182/blood-2017-02-766121
.
[22]
Andre MPE , Girinsky T , Federico M ,et al. Early positron emission tomography response-adapted treatment in stage Ⅰ and Ⅱ Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial[J]. J Clin Oncol, 2017,35(16)：1786-1794. DOI：
10.1200/JCO.2016.68.6394
.
[23]
Engert A , Plutschow A , Eich HT ,et al. Reduced treatment intensity in patients with early-stage Hodgkin′s lymphoma[J]. N Engl J Med, 2010,363(7)：640-652. DOI：
10.1056/NEJMoa1000067
.
[24]
Hoppe RT , Advani RH , Ai WZ ,et al. Hodgkin lymphoma[J]. J Natl Compr Canc Netw, 2011,9(9)：1020-1058. DOI：
10.6004/jnccn.2011.0086
.
[25]
Meyer RM , Gospodarowicz MK , Connors JM ,et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin′s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2005,23(21)：4634-4642. DOI：
10.1200/JCO.2005.09.085
.
[26]
Sasse S , Brockelmann PJ , Goergen H ,et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials[J]. J Clin Oncol, 2017,35(18)：1999-2007. DOI：
10.1200/JCO.2016.70.9410
.
[27]
Barrington SF , Phillips EH , Counsell N ,et al. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study[J]. J Clin Oncol, 2019,37(20)：1732-1741. DOI:
10.1200/JCO.18.01799
.
[28]
Fuchs M , Goergen H , Kobe C ,et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase Ⅲ HD16 trial by the German Hodgkin study group[J]. J Clin Oncol, 2019,37(31)：2835-2845. DOI：
10.1200/jco.19.00964
.
[29]
von Tresckow B , Kreissl S , Goergen H ,et al. Intensive treatment strategies in advanced-stage Hodgkin′s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials[J]. Lancet Haematol, 2018,5(10)：e462-e473. DOI：
10.1016/S2352-3026(18)30140-6
.
[30]
Casasnovas RO , Bouabdallah R , Brice P ,et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma(AHL2011): a randomised, multicentre, non-inferiority, phase 3 study[J]. Lancet Oncol, 2019,20(2)：202-215. DOI：
10.1016/S1470-2045(18)30784-8
.
[31]
Gallamini A , Tarella C , Viviani S ,et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial[J]. J Clin Oncol, 2018,36(5)：454-462. DOI：
10.1200/JCO.2017.75.2543
.
[32]
Zinzani PL , Broccoli A , Gioia DM ,et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase Ⅱ part of the HD0801 study[J]. J Clin Oncol, 2016,34(12)：1376-1385. DOI：
10.1200/JCO.2015.63.0699
.
[33]
Borchmann P , Goergen H , Kobe C ,et al. PET-guided treatment in patients with advanced-stage Hodgkin′s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group[J]. Lancet, 2017,390(10114)：2790-2802. DOI：
10.1016/S0140-6736(17)32134-7
.
[34]
Johnson P , Federico M , Kirkwood A ,et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin′s lymphoma[J]. N Engl J Med, 2016,374(25)：2419-2429. DOI：
10.1056/NEJMoa1510093
.
[35]
Straus DJ , Dlugosz-Danecka M , Alekseev S ,et al. Brentuximab vedotin with chemotherapy for stage Ⅲ/Ⅳ classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study[J]. Blood, 2020,135(10)：735-742. DOI：
10.1182/blood.2019003127
.
[36]
Voorhees TJ , Beaven AW . Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma[J]. Cancers (Basel), 2020,12(10)：2887. DOI：
10.3390/cancers12102887
.
[37]
Ansell SM . Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2018,93(5)：704-715. DOI：
10.1002/ajh.25071
.
[38]
Younes A , Santoro A , Shipp M ,et al. Nivolumab for classical Hodgkin′s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial[J]. Lancet Oncol, 2016,17(9)：1283-1294. DOI：
10.1016/S1470-2045(16)30167-X
.
[39]
Chen R , Zinzani PL , Fanale MA ,et al. Phase Ⅱ study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma[J]. J Clin Oncol, 2017,35(19)：2125-2132. DOI：
10.1200/JCO.2016.72.1316
.
[40]
Shi Y , Su H , Song Y ,et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2019,6(1)：e12-e19. DOI：
10.1016/S2352-3026(18)30192-3
.
[41]
Song Y , Gao Q , Zhang H ,et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study[J]. Leukemia, 2020,34(2)：533-542. DOI：
10.1038/s41375-019-0545-2
.
[42]
Song Y , Wu J , Chen X ,et al. A single-arm, multicenter, phase Ⅱ study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019,25(24)：7363-7369. DOI：
10.1158/1078-0432.CCR-19-1680
.
[43]
Hasenclever D , Diehl V . A prognostic score for advanced Hodgkin′s disease. International prognostic factors project on advanced Hodgkin′s disease[J]. N Engl J Med, 1998,339(21)：1506-1514. DOI：
10.1056/NEJM199811193392104
.
[44]
Wang Q . Prognostic factors of Hodgkin lymphoma in China[D]. Beijing：Peking Union Medical College (Department of medicine, Tsinghua University) & Chinese Academy of Medical Sciences, 2017. DOI：
10.7666/d.y3277653
.
[45]
Al-Hamadani M , Habermann TM , Cerhan JR ,et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the national cancer data base from 1998 to 2011[J]. Am J Hematol, 2015,90(9)：790-795. DOI：
10.1002/ajh.24086
.
[46]
Sun J , Yang Q , Lu Z ,et al. Distribution of lymphoid neoplasms in China: analysis of 4，638 cases according to the World Health Organization classification[J]. Am J Clin Pathol, 2012,138(3)：429-434. DOI：
10.1309/AJCP7YLTQPUSDQ5C
.
[47]
Shi Y , Han Y , Yang J ,et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1，085 WHO classified cases in a single institution in China[J]. Chin J Cancer Res, 2019,31(1)：152-161. DOI：
10.21147/j.issn.1000-9604.2019.01.10
.
[48]
Rosenwald A , Wright G , Chan WC ,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002,346(25)：1937-1947. DOI：
10.1056/NEJMoa012914
.
[49]
Hans CP , Weisenburger DD , Greiner TC ,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004,103(1)：275-282. DOI：
10.1182/blood-2003-05-1545
.
[50]
Green TM , Young KH , Visco C ,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012,30(28)：3460-3467. DOI：
10.1200/JCO.2011.41.4342
.
[51]
International Non-Hodgkin′s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin′s lymphoma[J]. N Engl J Med, 1993,329(14)：987-994. DOI：
10.1056/NEJM199309303291402
.
[52]
Sehn LH , Berry B , Chhanabhai M ,et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood, 2007,109(5)：1857-1861. DOI：
10.1182/blood-2006-08-038257
.
[53]
Zhou Z , Sehn LH , Rademaker AW ,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014,123(6)：837-842. DOI：
10.1182/blood-2013-09-524108
.
[54]
石远凯，刘鹏，杨晟，等. 注射用聚乙二醇化重组人粒细胞集落刺激因子Ⅰ期临床耐受性试验[J]. 癌症， 2006,25(4)：495-500. DOI：
10.3969/j.issn.1000-467X.2006.04.022
.
Shi YK , Liu P , Yang S ,et al. Phase Ⅰ clinicai trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor[J]. Chin J Cancer, 2006,25(4)：495-500. DOI：
10.3969/j.issn.1000-467X.2006.04.022
.
[55]
石远凯，何小慧，杨晟，等. 聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J]. 中华医学杂志， 2006,86(48)：3414-3419. DOI：
10.3760/j:issn:0376-2491.2006.48.008
.
Shi YK , He XH , Yang S ,et al. Treatment of chemotherapy-induced neutropenia with pegylated recombinant human granulocyte colony-stimulating fator：a multi-center randomized controlled phase lI clinical study[J]. Natl Med J Chin, 2006,86(48)：3414-3419. DOI：
10.3760/j:issn:0376-2491.2006.48.008
.
[56]
Shi YK , Chen Q , Zhu YZ ,et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study[J]. Anticancer Drugs, 2013,24(6)：641-647. DOI：
10.1097/CAD.0b013e3283610b5d
.
[57]
Poeschel V , Held G , Ziepert M ,et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial[J]. Lancet, 2019,394(10216)：2271-2281. DOI：
10.1016/S0140-6736(19)33008-9
.
[58]
Lamy T , Damaj G , Soubeyran P ,et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma[J]. Blood, 2018,131(2)：174-181. DOI：
10.1182/blood-2017-07-793984
.
[59]
Persky DO , Unger JM , Spier CM ,et al. Phase Ⅱ study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: southwest oncology group study 0014[J]. J Clin Oncol, 2008,26(14)：2258-2263. DOI：
10.1200/JCO.2007.13.6929
.
[60]
Wasterlid T , Biccler JL , Brown PN ,et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a nordic lymphoma group population-based study[J]. Ann Oncol, 2018,29(8)：1882-1883. DOI：
10.1093/annonc/mdy184
.
[61]
Held G , Murawski N , Ziepert M ,et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma[J]. J Clin Oncol, 2014,32(11)：1112-1118. DOI：
10.1200/JCO.2013.51.4505
.
[62]
Pfreundschuh M , Kuhnt E , Trumper L ,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J]. Lancet Oncol, 2011,12(11)：1013-1022. DOI：
10.1016/S1470-2045(11)70235-2
.
[63]
Peyrade F , Jardin F , Thieblemont C ,et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2011,12(5)：460-468. DOI：
10.1016/S1470-2045(11)70069-9
.
[64]
Schmitz N , Zeynalova S , Nickelsen M ,et al. CNS international prognostic index: a risk model for cns relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. J Clin Oncol, 2016,34(26)：3150-3156. DOI：
10.1200/JCO.2015.65.6520
.
[65]
Vitolo U , Chiappella A , Ferreri AJ ,et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase Ⅱ trial[J]. J Clin Oncol, 2011,29(20)：2766-2772. DOI：
10.1200/JCO.2010.31.4187
.
[66]
Howlett C , Snedecor SJ , Landsburg DJ ,et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis[J]. Br J Haematol, 2015,170(4)：504-514. DOI：
10.1111/bjh.13463
.
[67]
Morris PG , Correa DD , Yahalom J ,et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome[J]. J Clin Oncol, 2013,31(31)：3971-3979. DOI：
10.1200/JCO.2013.50.4910
.
[68]
Thiel E , Korfel A , Martus P ,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial[J]. Lancet Oncol, 2010,11(11)：1036-1047. DOI：
10.1016/S1470-2045(10)70229-1
.
[69]
Philip T , Guglielmi C , Hagenbeek A ,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin′s lymphoma[J]. N Engl J Med, 1995,333(23)：1540-1545. DOI：
10.1056/NEJM199512073332305
.
[70]
Locke FL , Ghobadi A , Jacobson CA ,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019,20(1)：31-42. DOI：
10.1016/S1470-2045(18)30864-7
.
[71]
Schuster SJ , Bishop MR , Tam CS ,et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019,380(1)：45-56. DOI：
10.1056/NEJMoa1804980
.
[72]
Abramson JS , Palomba ML , Gordon LI ,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020,396(10254)：839-852. DOI：
10.1016/S0140-6736(20)31366-0
.
[73]
Sehn LH , Herrera AF , Flowers CR ,et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J]. J Clin Oncol, 2020,38(2)：155-165. DOI：
10.1200/JCO.19.00172
.
[74]
Shi Y , Zhang QY , Han XH ,et al. Phase 1 study comparing the safety, tolerability, pharmacokinetics, and pharmacodynamics similarity of HLX01 to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma[J]. Chin J Cancer Res, 2020. DOI：
10.21147/j.issn.1000-9604.2021.03.11
.
[75]
Shi Y , Song Y , Qin Y ,et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma[J]. J Hematol Oncol, 2020,13(1)：38. DOI：
10.1186/s13045-020-00871-9
.
[76]
Wang XM , Bassig BA , Wen JJ ,et al. Clinical analysis of 1 629 newly diagnosed malignant lymphomas in current residents of Sichuan province, China[J]. Hematol Oncol, 2016,34(4)：193-199. DOI：
10.1002/hon.2202
.
[77]
Yang QP , Zhang WY , Yu JB ,et al. Subtype distribution of lymphomas in southwest China: analysis of 6，382 cases using WHO classification in a single institution[J]. Diagn Pathol, 2011,6：77. DOI：
10.1186/1746-1596-6-77
.
[78]
Zhou Y , Qin Y , He X ,et al. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: a China single-center retrospective study[J]. Asia Pac J Clin Oncol, 2020：1-11. DOI：
10.1111/ajco.13463
.
[79]
Wilder RB , Jones D , Tucker SL ,et al. Long-term results with radiotherapy for stage Ⅰ-Ⅱ follicular lymphomas[J]. Int J Radiat Oncol Biol Phys, 2001,51(5)：1219-1227. DOI：
10.1016/s0360-3016(01)01747-3
.
[80]
Marcus R , Davies A , Ando K ,et al. Obinutuzumab for the first-line treatment of follicular lymphoma[J]. N Engl J Med, 2017,377(14)：1331-1344. DOI：
10.1056/NEJMoa1614598
.
[81]
Martin P , Jung SH , Pitcher B ,et al. A phase Ⅱ trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin′s lymphoma (NHL): CALGB 50803 (Alliance)[J]. Ann Oncol, 2017,28(11)：2806-2812. DOI：
10.1093/annonc/mdx496
.
[82]
Morschhauser F , Fowler NH , Feugier P ,et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma[J]. N Engl J Med, 2018,379(10)：934-947. DOI：
10.1056/NEJMoa1805104
.
[83]
van Oers MH , Van Glabbeke M , Giurgea L ,et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin′s lymphoma: long-term outcome of the EORTC 20981 phase Ⅲ randomized intergroup study[J]. J Clin Oncol, 2010,28(17)：2853-2858. DOI：
10.1200/JCO.2009.26.5827
.
[84]
Bachy E , Seymour JF , Feugier P ,et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study[J]. J Clin Oncol, 2019,37(31)：2815-2824. DOI：
10.1200/JCO.19.01073
.
[85]
Leonard JP , Trneny M , Izutsu K ,et al. AUGMENT: a phase Ⅲ study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2019,37(14)：1188-1199. DOI：
10.1200/JCO.19.00010
.
[86]
Sehn LH , Chua N , Mayer J ,et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2016,17(8)：1081-1093. DOI：
10.1016/S1470-2045(16)30097-3
.
[87]
Shi YK , Hong XN , Yang JL ,et al. Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study[J]. Chin Med J (Engl), 2021,134(11)：1299-1309. DOI：
10.1097/CM9.0000000000001463
.
[88]
Witzig TE , Wiernik PH , Moore T ,et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin′s lymphoma[J]. J Clin Oncol, 2009,27(32)：5404-5409. DOI：
10.1200/JCO.2008.21.1169
.
[89]
Salles G , Schuster SJ , de Vos S ,et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study[J]. Haematologica, 2017,102(4)：e156-e159. DOI：
10.3324/haematol.2016.151738
.
[90]
Dreyling M , Santoro A , Mollica L ,et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2017,35(35)：3898-3905. DOI：
10.1200/JCO.2017.75.4648
.
[91]
Matasar MJ , Capra M , Ozcan M ,et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021,22(5)：678-689. DOI：
10.1016/S1470-2045(21)00145-5
.
[92]
Flinn IW , Miller CB , Ardeshna KM ,et al. DYNAMO: a phase Ⅱ Study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma[J]. J Clin Oncol, 2019,37(11)：912-922. DOI：
10.1200/JCO.18.00915
.
[93]
Morschhauser F , Tilly H , Chaidos A ,et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial[J]. Lancet Oncol, 2020,21(11)：1433-1442. DOI：
10.1016/S1470-2045(20)30441-1
.
[94]
Montoto S , Lopez-Guillermo A , Altes A ,et al. Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression[J]. Ann Oncol, 2004,15(10)：1484-1489. DOI：
10.1093/annonc/mdh406
.
[95]
Federico M , Bellei M , Marcheselli L ,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project[J]. J Clin Oncol, 2009,27(27)：4555-4562. DOI：
10.1200/JCO.2008.21.3991
.
[96]
Arcaini L , Burcheri S , Rossi A ,et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT[J]. Ann Oncol, 2007,18(2)：346-350. DOI：
10.1093/annonc/mdl388
.
[97]
Arcaini L , Paulli M , Boveri E ,et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles[J]. Cancer, 2004,100(1)：107-115. DOI：
10.1002/cncr.11893
.
[98]
Thieblemont C , Berger F , Dumontet C ,et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed[J]. Blood, 2000,95(3)：802-806. DOI：
10.1007/s002770050019
.
[99]
Goda JS , Gospodarowicz M , Pintilie M ,et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy[J]. Cancer, 2010,116(16)：3815-3824. DOI：
10.1002/cncr.25226
.
[100]
Teckie S , Qi S , Chelius M ,et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma[J]. Ann Oncol, 2017,28(5)：1064-1069. DOI：
10.1093/annonc/mdx025
.
[101]
Martinelli G , Laszlo D , Ferreri AJ ,et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin′s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy[J]. J Clin Oncol, 2005,23(9)：1979-1983. DOI：
10.1200/JCO.2005.08.128
.
[102]
Siegel RL , Miller KD , Jemal A . Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1)：7-30. DOI：
10.3322/caac.21442
.
[103]
李小秋，李甘地，高子芬，等. 中国淋巴瘤亚型分布：国内多中心性病例10002例分析[J]. 诊断学理论与实践， 2012,11(2)：111-115. DOI：
10.3969/j.issn.1671-2870.2012.02.006
.
Li XQ , Li GD , Gao ZF ,et al. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases[J]. J Diagn Concepts Pract, 2012,11(2)：111-115. DOI：
10.3969/j.issn.1671-2870.2012.02.006
.
[104]
Eichhorst B , Fink AM , Bahlo J ,et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial[J]. Lancet Oncol, 2016,17(7)：928-942. DOI：
10.1016/S1470-2045(16)30051-1
.
[105]
Hallek M , Fischer K , Fingerle-Rowson G ,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial[J]. Lancet, 2010,376(9747)：1164-1174. DOI：
10.1016/S0140-6736(10)61381-5
.
[106]
Burger JA , Tedeschi A , Barr PM ,et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015,373(25)：2425-2437. DOI：
10.1056/NEJMoa1509388
.
[107]
Burger JA , Barr PM , Robak T ,et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study[J]. Leukemia, 2020,34(3)：787-798. DOI：
10.1038/s41375-019-0602-x
.
[108]
Fischer K , Al-Sawaf O , Bahlo J ,et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions[J]. N Engl J Med, 2019,380(23)：2225-2236. DOI：
10.1056/NEJMoa1815281
.
[109]
Sharman JP , Egyed M , Jurczak W ,et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial[J]. Lancet, 2020,395(10232)：1278-1291. DOI：
10.1016/S0140-6736(20)30262-2
.
[110]
Chang JE , Havighurst T , Kim K ,et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study[J]. Br J Haematol, 2016,173(2)：283-291. DOI：
10.1111/bjh.13957
.
[111]
Byrd JC , Furman RR , Coutre SE ,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2013,369(1)：32-42. DOI：
10.1056/NEJMoa1215637
.
[112]
Xu W , Yang S , Zhou K ,et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study[J]. J Hematol Oncol, 2020,13(1)：48. DOI：
10.1186/s13045-020-00884-4
.
[113]
Xu W , Song Y , Li Z ,et al. Safety, tolerability and efficacy of orelabrutinib, once a day, to treat Chinese patients with relapsed or refractory chronic lymphocytic leukemia/small cell leukemia[J]. Blood, 2019,134(S1)：4319. DOI：
10.1182/blood-2019-123331
.
[114]
Seymour JF , Kipps TJ , Eichhorst B ,et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia[J]. N Engl J Med, 2018,378(12)：1107-1120. DOI：
10.1056/NEJMoa1713976
.
[115]
Furman RR , Sharman JP , Coutre SE ,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2014,370(11)：997-1007. DOI：
10.1056/NEJMoa1315226
.
[116]
Osterborg A , Jewell RC , Padmanabhan-Iyer S ,et al. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study[J]. Haematologica, 2015,100(8)：e311-e314. DOI：
10.3324/haematol.2014.121459
.
[117]
Flinn IW , Hillmen P , Montillo M ,et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL[J]. Blood, 2018,132(23)：2446-2455. DOI：
10.1182/blood-2018-05-850461
.
[118]
International CLLIPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data[J]. Lancet Oncol, 2016,17(6)：779-790. DOI：
10.1016/S1470-2045(16)30029-8
.
[119]
A clinical evaluation of the international lymphoma study group classification of non-Hodgkin′s lymphoma. The non-Hodgkin′s lymphoma classification project[J]. Blood, 1997,89(11)：3909-3918.
[120]
Sant M , Allemani C , Tereanu C ,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project[J]. Blood, 2010,116(19)：3724-3734. DOI：
10.1182/blood-2010-05-282632
.
[121]
Determann O , Hoster E , Ott G ,et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the German low grade lymphoma study group[J]. Blood, 2008,111(4)：2385-2387. DOI：
10.1182/blood-2007-10-117010
.
[122]
Eskelund CW , Dahl C , Hansen JW ,et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy[J]. Blood, 2017,130(17)：1903-1910. DOI：
10.1182/blood-2017-04-779736
.
[123]
Flinn IW , van der Jagt R , Kahl B ,et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study[J]. J Clin Oncol, 2019,37(12)：984-991. DOI：
10.1200/JCO.18.00605
.
[124]
Rummel MJ , Niederle N , Maschmeyer G ,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial[J]. Lancet, 2013,381(9873)：1203-1210. DOI：
10.1016/S0140-6736(12)61763-2
.
[125]
Robak T , Huang H , Jin J ,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma[J]. N Engl J Med, 2015,372(10)：944-953. DOI：
10.1056/NEJMoa1412096
.
[126]
Ruan J , Martin P , Shah B ,et al. Lenalidomide plus rituximab as initial treatment for mantle-Cell lymphoma[J]. N Engl J Med, 2015,373(19)：1835-1844. DOI：
10.1056/NEJMoa1505237
.
[127]
Wang ML , Rule S , Martin P ,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2013,369(6)：507-516. DOI：
10.1056/NEJMoa1306220
.
[128]
Li G , Liu X , Chen X . Simultaneous development of zanubrutinib in the USA and China[J]. Nat Rev Clin Oncol, 2020,17(10)：589-590. DOI：
10.1038/s41571-020-0414-y
.
[129]
Song Y , Zhou K , Zou D ,et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton′s tyrosine kinase[J]. Clin Cancer Res, 2020,26(16)：4216-4224. DOI：
10.1158/1078-0432.CCR-19-3703
.
[130]
Song Y , Song Y , Liu L ,et al. Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase Ⅱ study[J]. Blood, 2019,134(S1)：755. DOI：
10.1182/blood-2019-126305
.
[131]
Goy A , Sinha R , Williams ME ,et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase Ⅱ MCL-001 (EMERGE) study[J]. J Clin Oncol, 2013,31(29)：3688-3695. DOI：
10.1200/JCO.2013.49.2835
.
[132]
Fisher RI , Bernstein SH , Kahl BS ,et al. Multicenter phase Ⅱ study of bortezomib in patients with relapsed or refractory mantle cell lymphoma[J]. J Clin Oncol, 2006,24(30)：4867-4874. DOI：
10.1200/JCO.2006.07.9665
.
[133]
Geisler CH , Kolstad A , Laurell A ,et al. The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)[J]. Blood, 2010,115(8)：1530-1533. DOI：
10.1182/blood-2009-08-236570
.
[134]
Hoster E , Dreyling M , Klapper W ,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma[J]. Blood, 2008,111(2)：558-565. DOI：
10.1182/blood-2007-06-095331
.
[135]
Hoster E , Rosenwald A , Berger F ,et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network[J]. J Clin Oncol, 2016,34(12)：1386-1394. DOI：
10.1200/JCO.2015.63.8387
.
[136]
Blum KA , Lozanski G , Byrd JC . Adult Burkitt leukemia and lymphoma[J]. Blood, 2004,104(10)：3009-3020. DOI：
10.1182/blood-2004-02-0405
.
[137]
Swerdlow SH , Campo E , Pileri SA ,et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016,127(20)：2375-2390. DOI：
10.1182/blood-2016-01-643569
.
[138]
Dunleavy K , Pittaluga S , Shovlin M ,et al. Low-intensity therapy in adults with Burkitt′s lymphoma[J]. N Engl J Med, 2013,369(20)：1915-1925. DOI：
10.1056/NEJMoa1308392
.
[139]
Thomas DA , Faderl S , O′Brien S ,et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia[J]. Cancer, 2006,106(7)：1569-1580. DOI：
10.1002/cncr.21776
.
[140]
Burkhardt B , Hermiston ML . Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities[J]. Br J Haematol, 2019,185(6)：1158-1170. DOI：
10.1111/bjh.15793
.
[141]
Chen H , Qin Y , Yang J ,et al. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma[J]. Ann Hematol, 2020,99(12)：2847-2857. DOI：
10.1007/s00277-020-04195-z
.
[142]
Cortelazzo S , Ferreri A , Hoelzer D ,et al. Lymphoblastic lymphoma[J]. Crit Rev Oncol Hematol, 2017,113：304-317. DOI：
10.1016/j.critrevonc.2017.03.020
.
[143]
Jain P , Kantarjian H , Jain N ,et al. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens[J]. Am J Hematol, 2017,92(10)：E595-E597. DOI：
10.1002/ajh.24833
.
[144]
Abaza Y , M Kantarjian H , Faderl S ,et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma[J]. Am J Hematol, 2018,93(1)：91-99. DOI：
10.1002/ajh.24947
.
[145]
Pui CH . Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment[J]. Hematology Am Soc Hematol Educ Program, 2006:142-146. DOI：
10.1182/asheducation-2006.1.142
.
[146]
Armitage JO . The aggressive peripheral T-cell lymphomas: 2017[J]. Am J Hematol, 2017,92(7)：706-715. DOI：
10.1002/ajh.24791
.
[147]
Vose J , Armitage J , Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008,26(25)：4124-4130. DOI：
10.1200/JCO.2008.16.4558
.
[148]
Corradini P , Vitolo U , Rambaldi A ,et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma[J]. Leukemia, 2014,28(9)：1885-1891. DOI：
10.1038/leu.2014.79
.
[149]
d′Amore F , Relander T , Lauritzsen GF ,et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01[J]. J Clin Oncol, 2012,30(25)：3093-3099. DOI：
10.1200/JCO.2011.40.2719
.
[150]
Fossard G , Broussais F , Coelho I ,et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers[J]. Ann Oncol, 2018,29(3)：715-723. DOI：
10.1093/annonc/mdx787
.
[151]
Reimer P , Rudiger T , Geissinger E ,et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study[J]. J Clin Oncol, 2009,27(1)：106-113. DOI：
10.1200/JCO.2008.17.4870
.
[152]
Gui L , Shi YK , He XH ,et al. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis[J]. Int J Hematol, 2014,99(1)：69-78. DOI：
10.1007/s12185-013-1465-y
.
[153]
Zhang XM , Li YX , Wang WH ,et al. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified[J]. Int J Radiat Oncol Biol Phys, 2013,85(4)：1051-1056. DOI：
10.1016/j.ijrobp.2012.08.015
.
[154]
Shi Y , Dong M , Hong X ,et al. Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol, 2015,26(8)：1766-1771. DOI：
10.1093/annonc/mdv237
.
[155]
Shi Y , Jia B , Xu W ,et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol, 2017,10(1)：69. DOI：
10.1186/s13045-017-0439-6
.
[156]
O′Connor OA , Horwitz S , Masszi T ,et al. Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN-19) study[J]. J Clin Oncol, 2015,33(23)：2492-2499. DOI：
10.1200/JCO.2014.59.2782
.
[157]
Coiffier B , Pro B , Prince HM ,et al. Results from a pivotal, open-label, phase Ⅱ study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy[J]. J Clin Oncol, 2012,30(6)：631-636. DOI：
10.1200/JCO.2011.37.4223
.
[158]
Coiffier B , Pro B , Prince HM ,et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses[J]. J Hematol Oncol, 2014,7：11. DOI：
10.1186/1756-8722-7-11
.
[159]
O′Connor OA , Pro B , Pinter-Brown L ,et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study[J]. J Clin Oncol, 2011,29(9)：1182-1189. DOI：
10.1200/JCO.2010.29.9024
.
[160]
Horwitz SM , Advani RH , Bartlett NL ,et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin[J]. Blood, 2014,123(20)：3095-3100. DOI：
10.1182/blood-2013-12-542142
.
[161]
Zinzani PL , Venturini F , Stefoni V ,et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome[J]. Ann Oncol, 2010,21(4)：860-863. DOI：
10.1093/annonc/mdp508
.
[162]
Damaj G , Gressin R , Bouabdallah K ,et al. Results from a prospective, open-label, phase Ⅱ trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial[J]. J Clin Oncol, 2013,31(1)：104-110. DOI：
10.1200/JCO.2012.43.7285
.
[163]
Toumishey E , Prasad A , Dueck G ,et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma[J]. Cancer, 2015,121(5)：716-723. DOI：
10.1002/cncr.29103
.
[164]
Zinzani PL , Musuraca G , Tani M ,et al. Phase Ⅱ trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007,25(27)：4293-4297. DOI：
10.1200/JCO.2007.11.4207
.
[165]
Velasquez WS , Cabanillas F , Salvador P ,et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)[J]. Blood, 1988,71(1)：117-122. DOI：
10.1136/adc.48.8.583
.
[166]
Velasquez WS , McLaughlin P , Tucker S ,et al. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study[J]. J Clin Oncol, 1994,12(6)：1169-1176. DOI：
10.1200/JCO.1994.12.6.1169
.
[167]
Parkin S , Connors JM , Sehn LH ,et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as secondary chemotherapy in relapsed/refractory peripheral T-cell lymphoma[J]. Blood, 2013,122(21)：4345-4345. DOI：
10.1182/blood.V122.21.4345.4345
.
[168]
Park BB , Kim WS , Suh C ,et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial[J]. Ann Hematol, 2015,94(11)：1845-1851. DOI：
10.1007/s00277-015-2468-y
.
[169]
Qian Z , Song Z , Zhang H ,et al. Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma[J]. Biomed Res Int, 2015,2015：606752. DOI：
10.1155/2015/606752
.
[170]
Horwitz S , Moskowitz C , Kewalramani T ,et al. Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat[J]. Invenio Revista De Investigación Académica, 2005,10(18)：117-127. DOI：
10.1271/bbb.65.848
.
[171]
Hong X , Song Y , Huang H ,et al. Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study[J]. Target Oncol, 2019,14(2)：149-158. DOI：
10.1007/s11523-019-00630-y
.
[172]
Jia B , Hu S , Yang J ,et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas[J]. Hematology, 2016,21(9)：536-541. DOI：
10.1080/10245332.2016.1152084
.
[173]
Gallamini A , Stelitano C , Calvi R ,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study[J]. Blood, 2004,103(7)：2474-2479. DOI：
10.1182/blood-2003-09-3080
.
[174]
Sethi TK , Montanari F , Foss F ,et al. How we treat advanced stage cutaneous T-cell lymphoma-mycosis fungoides and Sézary syndrome[J]. Br J Haematol, 2021. DOI：
10.1111/bjh.17458
.
[175]
Kim EJ , Hess S , Richardson SK ,et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma[J]. J Clin Invest, 2005,115(4)：798-812. DOI：
10.1172/JCI24826
.
[176]
Zackheim HS . Treatment of patch-stage mycosis fungoides with topical corticosteroids[J]. Dermatol Ther, 2003,16(4)：283-287. DOI：
10.1111/j.1396-0296.2003.01639.x
.
[177]
Lessin SR , Duvic M , Guitart J ,et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides[J]. JAMA Dermatol, 2013,149(1)：25-32. DOI：
10.1001/2013.jamadermatol.541
.
[178]
Zackheim HS . Topical carmustine (BCNU) in the treatment of mycosis fungoides[J]. Dermatol Ther, 2003,16(4)：299-302. DOI：
10.1111/j.1396-0296.2003.01641.x
.
[179]
Diederen PV , van Weelden H , Sanders CJ ,et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study[J]. J Am Acad Dermatol, 2003,48(2)：215-219. DOI：
10.1067/mjd.2003.80
.
[180]
Heald P , Mehlmauer M , Martin AG ,et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase Ⅲ clinical trial[J]. J Am Acad Dermatol, 2003,49(5)：801-815. DOI：
10.1016/s0190-9622(03)01475-0
.
[181]
Deeths MJ , Chapman JT , Dellavalle RP ,et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream[J]. J Am Acad Dermatol, 2005,52(2)：275-280. DOI：
10.1016/j.jaad.2004.04.049
.
[182]
Martinez-Gonzalez MC , Verea-Hernando MM , Yebra-Pimentel MT ,et al. Imiquimod in mycosis fungoides[J]. Eur J Dermatol, 2008,18(2)：148-152. DOI：
10.1684/ejd.2008.0352
.
[183]
Harrison C , Young J , Navi D ,et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides[J]. Int J Radiat Oncol Biol Phys, 2011,81(4)：e651-657. DOI：
10.1016/j.ijrobp.2011.01.023
.
[184]
Olsen EA , Kim YH , Kuzel TM ,et al. Phase Ⅱb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007,25(21)：3109-3115. DOI：
10.1200/JCO.2006.10.2434
.
[185]
Whittaker SJ , Demierre MF , Kim EJ ,et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2010,28(29)：4485-4491. DOI：
10.1200/JCO.2010.28.9066
.
[186]
Duvic M , Hymes K , Heald P ,et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase Ⅱ-Ⅲ trial results[J]. J Clin Oncol, 2001,19(9)：2456-2471. DOI：
10.1200/JCO.2001.19.9.2456
.
[187]
Prince HM , Kim YH , Horwitz SM ,et al. Brentuximab vedotin or physician′s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017,390(10094):555-566. DOI：
10.1016/S0140-6736(17)31266-7
.
[188]
Kim YH , Bagot M , Pinter-Brown L ,et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018,19(9)：1192-1204. DOI：
10.1016/S1470-2045(18)30379-6
.
[189]
Scarisbrick JJ , Prince HM , Vermeer MH ,et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model[J]. J Clin Oncol, 2015,33(32)：3766-3773. DOI：
10.1200/JCO.2015.61.7142
.
[190]
Au WY , Weisenburger DD , Intragumtornchai T ,et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-Cell lymphoma project[J]. Blood, 2009,113(17)：3931-3937. DOI：
10.1182/blood-2008-10-185256
.
[191]
Huang MJ , Jiang Y , Liu WP ,et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract[J]. Int J Radiat Oncol Biol Phys, 2008,70(1)：166-174. DOI：
10.1016/j.ijrobp.2007.05.073
.
[192]
Yamaguchi M , Tobinai K , Oguchi M ,et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211[J]. J Clin Oncol, 2012,30(32)：4044-4046. DOI：
10.1200/JCO.2012.45.6541
.
[193]
Kim SJ , Kim K , Kim BS ,et al. Phase Ⅱ trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study[J]. J Clin Oncol, 2009,27(35)：6027-6032. DOI：
10.1200/JCO.2009.23.8592
.
[194]
Wang L , Wang ZH , Chen XQ ,et al. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long-term follow-up[J]. Oncol Lett, 2015,10(2)：1036-1040. DOI：
10.3892/ol.2015.3327
.
[195]
Zhang L , Jiang M , Xie L ,et al. Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal type, extranodal natural killer/T-cell lymphoma[J]. Cancer Med, 2016,5(1)：33-40. DOI：
10.1002/cam4.569
.
[196]
Lunning M , Pamer E , Maragulia J ,et al. Modified SMILE (mSMILE) is active in the treatment of extranodal natural killer/T-cell lymphoma: a single center US experience[J]. Clinical Lymphoma, Myeloma and Leukemia, 2014,14：S143-S144. DOI：
10.1016/j.clml.2014.06.080
[197]
Wang JH , Wang H , Wang YJ ,et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J]. Oncotarget, 2016,7(23)：35412-35422. DOI：
10.18632/oncotarget.8643
.
[198]
Yamaguchi M , Kwong YL , Kim WS ,et al. Phase Ⅱ study of SMILE chemotherapy for newly diagnosed stage Ⅳ，relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell tumor study group study[J]. J Clin Oncol, 2011,29(33)：4410-4416. DOI：
10.1200/JCO.2011.35.6287
.
[199]
Kim SJ , Yoon DH , Jaccard A ,et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet Oncol, 2016,17(3)：389-400. DOI：
10.1016/S1470-2045(15)00533-1
.
[200]
中国抗癌协会淋巴瘤专业委员会，中国医师协会肿瘤医师分会，中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤多学科诊疗模式实施指南[J]. 中华肿瘤杂志， 2021,43(2)：163-166. DOI：
10.3760/cma.j.cn112152-20201109-00971
.
China Anti-Cancer Association Lymphoma Committee,Chinese Association for Clinical Oncologists,Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare. Clinical practice guideline for multi-disciplinary treatment strategy of lymphoma in China[J]. Chin J Oncol, 2021,43(2)：163-166. DOI：
10.3760/cma.j.cn112152-20201109-00971
备注信息
A
石远凯，国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科 抗肿瘤分子靶向药物临床研究北京市重点实验室 100021，Email：
nc.defcaab.smaciciaknauys
B
所有作者均声明不存在利益冲突
C
重大新药创制科技重大专项 (2017ZX09304015)
中国医学科学院医学与健康科技创新工程 (2016-I2M-1-001)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
中国心力衰竭诊断和治疗指南2024
中华医学会心血管病学分会 等 中华心血管病杂志 2024,52(03)
中国噬血细胞综合征诊断与治疗指南（2022年版）
中国医师协会血液科医师分会 等 中华医学杂志 2022,102(20)
中国老年糖尿病诊疗指南（2021年版）
国家老年医学中心 等 中华糖尿病杂志 2021,13(01)
中国艾滋病诊疗指南(2021年版)
中华医学会感染病学分会艾滋病丙型肝炎学组 等 中华传染病杂志 2021,39(12)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
